http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1200812-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d78cd2835221849f6a74e6349185819 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-40 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-40 |
| filingDate | 1982-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1986-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_323acba851873631b8190ad8ad09f245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22889e55742f0158ef957c9a6570110f |
| publicationDate | 1986-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1200812-A |
| titleOfInvention | Bicyclic derivatives as histamine h-2 receptor antagonists |
| abstract | ABSTRACT The invention relates to bicyclic derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a quanidine derivative of the formula I:- I in which R1 and R2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkyl-alkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R1 and R2 is halogen substituted, or R3 is hydrogen and R1 is R3-E-W in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O, S, SO, SO2 or NR4 in which R4 is H or 1-6C alkyl, R3 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R3 and R4 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring, or R2 is H and R1 is H, 1-10C alkyl, 3-8C cyclo-alkyl, 4-14C cycloalkylalkyl, 3-6C alkenyl, 3-6C alkynyl, 1-6C alkanoyl, 6-10C aryl, 7-11C aralkyl or 7-11C aroyl; ring X is a heterocyclic ring as defined in the spec-ification; A is phenylene or 5-7C cycloalkylene, or a 1-8C alkylene into which is optionally inserted one or two groups; ring Y is a heterocyclic ring described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described. |
| priorityDate | 1981-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 233.